SavedAdd your journal

Journals / Sağlık Bilimlerinde İleri Araştırmalar Dergisi / 2022 / Cilt: 5 - Sayı: 1

MOLECULAR BIOLOGY AND GENETIC STUDIES IN COMBATING THE NEW CORONAVIRUS (COVID-19) OUTBREAK

YENİ KORONAVİRÜS (COVİD-19) SALGINIYLA MÜCADELEDE MOLEKÜLER BİYOLOJİ VE GENETİK ÇALIŞMALARI

Pervin Elvan TOKGÜN
Sude DEDEOĞLU
Ayşe Gaye TOMATIR
Pages
41–49
Publication Date
2022-02-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review aims to give information about the molecular structure and genetic features of SARSCoV- 2 virus, laboratory diagnostic methods, potential therapeutic drugs and vaccine studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The new type of coronavirus (SARS-CoV-2), which is transmitted from person to person and causes Severe Acute Respiratory Distress Syndrome (SARS), emerged in Wuhan, China in December 2019.
📊
Key Findings & Data:The continuation of the COVID-19 pandemic has made it necessary to develop an effective vaccine against SARS-CoV-2.
💡
Conclusion & Impact:This review aims to give information about the molecular structure and genetic features of SARSCoV- 2 virus, laboratory diagnostic methods, potential therapeutic drugs and vaccine studies.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:SARS-COV-2 · Moleküler Genetik yöntemler · COVİD-19 Tedavisi

Abstract

The new type of coronavirus (SARS-CoV-2), which is transmitted from person to person and causes Severe Acute Respiratory Distress Syndrome (SARS), emerged in Wuhan, China in December 2019. The definitive diagnosis of the coronavirus, which is transmitted from person to person through droplets, is given through PCR-based tests. The continuation of the COVID-19 pandemic has made it necessary to develop an effective vaccine against SARS-CoV-2. Vaccines developed against COVID-19 can be classified as inactivated/live virus vaccines, recombinant protein vaccines/ vectored vaccines or RNA/DNA vaccines. This review aims to give information about the molecular structure and genetic features of SARSCoV- 2 virus, laboratory diagnostic methods, potential therapeutic drugs and vaccine studies.

Özet

İnsandan insana bulaşan ve Ağır Akut Solunum Yetmezliği Sendromuna (SARS) neden olan yeni tip koronavirüs (SARS-CoV-2) 2019 yılı Aralık ayında Çin’in Wuhan şehrinde ortaya çıkmıştır. Damlacıklar yoluyla insandan insana bulaşan koronavirüsün kesin tanısı PZR tabanlı testler ile verilmektedir. COVID-19 pandemisinin devam etmesi SARS-CoV-2 ‘ye karşı etkili bir aşı geliştirmenin gerekliliği ortaya çıkmıştır. COVID-19’a karşı geliştirilen aşılar inaktive edilmiş / canlı virüs aşıları, rekombinant protein aşıları / vektörlü aşılar ve RNA/ DNA aşıları olarak sınıflandırılabilir. Bu derlemede SARS-CoV-2 virüsünün moleküler yapısı ve genetik özellikleri, laboratuvar teşhis metotları, potansiyel terapötik ilaçlar ve aşı çalışmaları hakkında bilgi verilmesi amaçlanmıştır.

🔖

Cite This Article

TOKGÜN, P. E., DEDEOĞLU, S., TOMATIR, A. G. (2022). MOLECULAR BIOLOGY AND GENETIC STUDIES IN COMBATING THE NEW CORONAVIRUS (COVID-19) OUTBREAK. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, Cilt: 5 - Sayı: 1, 41–49. https://ajindex.com/articles/391940

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Ünal N. Yeni Koranavirüs Hastalığının Etiyolojisi. Eurasian JHS 2020;3:95-101
  2. Ünal N. Yeni Koranavirüs Hastalığının Etiyolojisi. Eurasian JHS 2020;3:95-101
  3. Ünal N. Yeni Koranavirüs Hastalığının Etiyolojisi. Eurasian JHS 2020;3:95-101
  4. T.C. Sağlık Bakanlığı. COVID-19 (SARS-COV-2 Enfeksiyonu) Genel Bilgiler, Epidemiyoloji ve Tanı, Kasım 2020. Erişim adresi: https:// covid19.saglik.gov.tr/Eklenti/39551/0/covid-19rehberigenelbilgil erepidemiyolojivetanipdf.pdf
  5. WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020. https://www.who.int/director-general/ speeches/detail/who-director-general-s-opening-remarks-at-themedia- briefing-on-COVID-19-26-march-2021
  6. Arabacı Ç, Aydın Tutak G, Eroğlu Kesim B, Ertürk B, Ak K, Ağaç E. The Characteristics of SARS-CoV-2 Virus and Microbiological Diagnosis. Eur Arc Med Res 2020;36(1):10-20
  7. Arabacı Ç, Aydın Tutak G, Eroğlu Kesim B, Ertürk B, Ak K, Ağaç E. The Characteristics of SARS-CoV-2 Virus and Microbiological Diagnosis. Eur Arc Med Res 2020;36(1):10-20
  8. Arabacı Ç, Aydın Tutak G, Eroğlu Kesim B, Ertürk B, Ak K, Ağaç E. The Characteristics of SARS-CoV-2 Virus and Microbiological Diagnosis. Eur Arc Med Res 2020;36(1):10-20. 5.Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020;5:562-9
  9. Anderson RM, Fraser C, Ghani AC, Donnelly CA, Riley S, Ferguson NM and et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci 2004;359(1447):1091–105
  10. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 2020;49(3):717-26
  11. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W and et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798): 270–3
  12. Öztan G, İşsever H. Yeni Koronavirüsün (COVID-19) Moleküler Yapısı ve Genomik Karakterizasyonu SABİAD 2020;3(2):61-71
  13. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020;12:372
  14. Heinz FX, Stiasny K. Profile of SARS-CoV-2. Wien Klin Wochenschr 2020;132: 635–44
  15. Schoeman D, Fielding BC. Coronavirus envelope protein: Current knowledge. Virol J 2019;16 (69):2-22
  16. Tang X